Therapie op maat: nut van nieuwe oncologische testen.

Translated title of the contribution: [Targeted therapy: the benefit of new oncological tests].

Carolien P. Schröder*, Karel G.M. Moons, E. G.E.Liesbeth de Vries

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    62 Downloads (Pure)

    Abstract

    An increasing number of targeted drug treatments are becoming available for many types of cancer. There is a great need for adequate biomarkers that can predict the effect of targeted therapy in individual cancer patients, in order to determine the correct oncological treatment per patient. This way, non-effective treatments can be spared, side-effects avoided, and costs reduced. Oestrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER2) are examples of standardized tests for breast cancer that have been validated in randomised studies. Data from randomised studies is also expected for gene expression profiles that correlate with tumour growth. Quantifying the predictive value of tests for anticipated treatment effects is costly and time-consuming. Given the increasing availability of targeted agents and diagnostic and prognostic techniques, alternative clinical study designs that can lead to quicker and more efficient verification are being sought in many different domains.

    Translated title of the contribution[Targeted therapy: the benefit of new oncological tests].
    Original languageDutch
    Article numberA4089
    Number of pages6
    JournalNederlands Tijdschrift voor Geneeskunde
    Volume155
    Issue number45
    Publication statusPublished - 9-Nov-2011

    Cite this